Intrommune Therapeutics

Intrommune is a biotechnology company based in New York City, specializing in the development of novel treatments for food allergies. The company operates in the healthcare sector, focusing on a unique oral mucosal immunotherapy (OMIT) platform. This platform embeds therapeutic agents into a functional toothpaste, allowing patients to receive daily treatment for food allergies while brushing their teeth. Intrommune's core technology aims to deliver allergenic proteins to the oral cavity, promoting immune tolerance without the need for ingestion. The company's primary clients are individuals suffering from food allergies, a market that includes over 32 million Americans. Intrommune's business model revolves around the commercialization of this innovative toothpaste, generating revenue through product sales. The company is committed to providing a safe, effective, and user-friendly solution for managing food allergies, potentially transforming the standard of care in this field.

Keywords: biotechnology, food allergies, immunotherapy, toothpaste, OMIT, allergenic proteins, immune tolerance, healthcare, daily treatment, New York City.